Correlation between circulating myeloid-derived suppressor cells and Th17 cells in esophageal cancer

World Journal of Gastroenterology

Volumn 18, Issue 38, 2012, Pages 5454-5461

  Jiao, Zhi Jun ^a   Gao, Jing Jing ^a   Hua, Sheng Hao ^a   Chen, De Yu ^a   Wang, Wen Hong ^b   Wang, Hui ^a   Wang, Xu Hui ^a   Xu, Hua Xi ^b  

^a AFFILIATED HOSPITAL OF JIANGSU UNIVERSITY   (China)

^b JIANGSU UNIVERSITY   (China)

Author keywords

Arginase I; Esophageal cancer; Inducible NO synthase; Myeloid derived suppressor cells; Peripheral blood mononuclear cells; Th17 cells

Indexed keywords

ARGINASE 1; CD4 ANTIGEN; CYTOKINE; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 17; INTERLEUKIN 6; MESSENGER RNA; RETINOID RELATED ORPHAN RECEPTOR GAMMA; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESOPHAGUS CANCER; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; MALE; MYELOID DERIVED SUPPRESSOR CELL; PERIPHERAL BLOOD MONONUCLEAR CELL; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; REAL TIME POLYMERASE CHAIN REACTION; SUPPRESSOR CELL; TH17 CELL;

EID: 84873187879     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v18.i38.5454     Document Type: Article

References (20)

1. Gabrilovich DI, Nagaraj S. Myeloid-derived suppressor cells as regulators of the immune system. Nat Rev Immunol 2009; 9: 162-174
2. Raychaudhuri B, Rayman P, Ireland J, Ko J, Rini B, Borden EC, Garcia J, Vogelbaum MA, Finke J. Myeloid-derived suppressor cell accumulation and function in patients with newly diagnosed glioblastoma. Neuro Oncol 2011; 13: 591-599
3. Brandau S, Trellakis S, Bruderek K, Schmaltz D, Steller G, Elian M, Suttmann H, Schenck M, Welling J, Zabel P, Lang S. Myeloid-derived suppressor cells in the peripheral blood of cancer patients contain a subset of immature neutrophils with impaired migratory properties. J Leukoc Biol 2011; 89: 311-317
4. Almand B, Clark JI, Nikitina E, van Beynen J, English NR, Knight SC, Carbone DP, Gabrilovich DI. Increased production of immature myeloid cells in cancer patients: a mechanism of immunosuppression in cancer. J Immunol 2001; 166: 678-689
5. Mandruzzato S, Solito S, Falisi E, Francescato S, Chiarion-Sileni V, Mocellin S, Zanon A, Rossi CR, Nitti D, Bronte V, Zanovello P. IL4Ralpha+ myeloid-derived suppressor cell expansion in cancer patients. J Immunol 2009; 182: 6562-6568
6. Gabitass RF, Annels NE, Stocken DD, Pandha HA, Middleton GW. Elevated myeloid-derived suppressor cells in pancreatic, esophageal and gastric cancer are an independent prognostic factor and are associated with significant elevation of the Th2 cytokine interleukin-13. Cancer Immunol Immunother 2011; 60: 1419-1430
7. Veltman JD, Lambers ME, van Nimwegen M, Hendriks RW, Hoogsteden HC, Aerts JG, Hegmans JP. COX-2 inhibition improves immunotherapy and is associated with decreased numbers of myeloid-derived suppressor cells in mesothelioma. Celecoxib influences MDSC function. BMC Cancer 2010; 10: 464
8. Hoechst B, Gamrekelashvili J, Manns MP, Greten TF, Korangy F. Plasticity of human Th17 cells and iTregs is orchestrated by different subsets of myeloid cells. Blood 2011; 117: 6532-6541
9. Chen D, Hu Q, Mao C, Jiao Z, Wang S, Yu L, Xu Y, Dai D, Yin L, Xu H. Increased IL-17-producing CD4(+) T cells in patients with esophageal cancer. Cell Immunol 2012; 272: 166-174
10. Lee JJ, Chang YL, Lai WL, Ko JY, Kuo MY, Chiang CP, Azuma M, Chen CW, Chia JS. Increased prevalence of interleukin-17-producing CD4(+) tumor infiltrating lymphocytes in human oral squamous cell carcinoma. Head Neck 2011; 33: 1301-1308
11. Wang J, Cai D, Ma B, Wu G, Wu J. Skewing the balance of regulatory T-cells and T-helper 17 cells in breast cancer patients. J Int Med Res 2011; 39: 691-701
12. Zamarron BF, Chen W. Dual roles of immune cells and their factors in cancer development and progression. Int J Biol Sci 2011; 7: 651-658
13. Martin-Orozco N, Muranski P, Chung Y, Yang XO, Yamazaki T, Lu S, Hwu P, Restifo NP, Overwijk WW, Dong C. T helper 17 cells promote cytotoxic T cell activation in tumor immunity. Immunity 2009; 31: 787-798
14. Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med 2009; 206: 1457-1464
15. Yin B, Ma G, Yen CY, Zhou Z, Wang GX, Divino CM, Casares S, Chen SH, Yang WC, Pan PY. Myeloid-derived suppressor cells prevent type 1 diabetes in murine models. J Immunol 2010; 185: 5828-5834
16. Haile LA, von Wasielewski R, Gamrekelashvili J, Krüger C, Bachmann O, Westendorf AM, Buer J, Liblau R, Manns MP, Korangy F, Greten TF. Myeloid-derived suppressor cells in inflammatory bowel disease: a new immunoregulatory pathway. Gastroenterology 2008; 135: 871-881, 881. e1-5
17. Ochoa AC, Zea AH, Hernandez C, Rodriguez PC. Arginase, prostaglandins, and myeloid-derived suppressor cells in renal cell carcinoma. Clin Cancer Res 2007; 13: 721s-726s
18. Wang WW, Wang ZM, Liu YY, Qin YH, Shen Q. [Increased level of Th17 cells in peripheral blood correlates with the development of hepatocellular carcinoma]. Zhonghua Zhong Liu Zazhi 2010; 32: 757-761
19. Deans DA, Wigmore SJ, Gilmour H, Paterson-Brown S, Ross JA, Fearon KC. Elevated tumour interleukin-1beta is associated with systemic inflammation: A marker of reduced survival in gastro-oesophageal cancer. Br J Cancer 2006; 95: 1568-1575
20. Ioannou M, Alissafi T, Lazaridis I, Deraos G, Matsoukas J, Gravanis A, Mastorodemos V, Plaitakis A, Sharpe A, Boumpas D, Verginis P. Crucial role of granulocytic myeloid-derived suppressor cells in the regulation of central nervous system autoimmune disease. J Immunol 2012; 188: 1136-1146